| Name | Nivolumab |
| Synonyms | Opdivo ONO 4538 MDX 1106 Nivolumab BMS 936558 Nivolumab (anti-PD-1) |
| CAS | 946414-94-4 |
| Physical and Chemical Properties | Bioactive Nivolumab (anti-PD-1) is a genetically engineered, human immunoglobulin (Ig)G4 monoclonal antibody, targeting the human cell surface receptor programmed death -1(PD-1, PCD-1) with negative immunomodulatory function; Also an inhibitor with immune checkpoint inhibitory activity and antitumor activity; MW:143.597 KD. |
| Use | nivolumab (trade name OPDIVO) is an anti-PD-1 monoclonal antibody that restores the anti-tumor effect of T cells by blocking the binding of PD-1 to its ligand PDL-1/2. Currently, nivolumab has been approved by the US FDA and the European Medicines Agency (EMA) for the treatment of renal cancer. |